Correction of Metabolic Acidosis in End Stage Renal Disease (ESRD)
NCT01640119 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 728
Last updated 2014-09-19
Summary
The investigators want to evaluate whether an original action based on the administration of alkali (mainly sodium bicarbonate) is able to significantly modify renal death and to reduce mortality due to cardiovascular events.
Methods: This is a proposal of Multicentric, prospective, cohort, randomized, open-label and controlled study.
The investigators will Randomize 728 patients with Chronic Kidney Disease(CKD) stage 3b (CKD-3b) and CKD stage 4: 364 of these patients will be included in the study group called Bicarbonate Group (Bic), in which levels of bicarbonate should be kept \> 24 mEq/l; the other 364 patients will included in the Usual Treatment Group (no-Bic).
Results: The aim of the Research Protocol is to demonstrate if that the optimal correction of uremic acidosis (with administration of sodium bicarbonate or of any other alkalinizing agent, e.g. sodium citrate) reduces renal and cardiovascular mortality.
Conclusions. In conclusion the Work Group of the Conservative Therapy for Chronic Renal Insufficiency proposes this cohort, randomized, controlled, prospective, multicentric study to evaluate the effects of correction of acidosis on the progression of the kidney disease considered as renal death in End-Stage Renal Disease (ESRD) patients.
Conditions
- Metabolic Acidosis
Interventions
- DIETARY_SUPPLEMENT
-
Bicarbonate
bicarbonate administration
Sponsors & Collaborators
-
Azienda Sanitaria ASL Avellino 2
lead OTHER
Principal Investigators
-
Biagio Di Iorio, MD, PhD · Azienda Sanitaria ASL Avellino 2
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-31
- Primary Completion
- 2014-12-31
- Completion
- 2017-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal
NCT01930370 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Metabolic Acidosis in Chronic Kidney Disease to Prevent Adverse Kidney and Cardiovascular Outcomes
NCT06545461 ·Status: COMPLETED ·Phase: NA
-
H+ Mobilization With Dialysate Bicarbonate Variation
NCT04020757 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)
NCT02692378 ·Status: COMPLETED ·Phase: PHASE4
-
Dietary Acid Reduction and Progression of Chronic Kidney Disease
NCT06046924 ·Status: COMPLETED ·Phase: NA
-
Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate
NCT06270134 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Metabolic Alkalosis in Heart Failure
NCT04740242 ·Status: COMPLETED
-
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
NCT01691053 ·Status: COMPLETED ·Phase: PHASE2
-
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
NCT02778516 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
NCT06814132 ·Status: COMPLETED ·Phase: PHASE1
-
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
NCT01855334 ·Status: WITHDRAWN ·Phase: PHASE4
-
Alkalinization by Urologists & Nephrologists
NCT03035812 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
NCT01687699 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure
NCT00527059 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
NCT02285920 ·Status: COMPLETED ·Phase: PHASE2
-
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
NCT04530448 ·Status: TERMINATED ·Phase: PHASE4
-
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01853553 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
NCT01598740 ·Status: COMPLETED ·Phase: PHASE1
-
Cardiovascular Protective Effect of Spironolactone in Hemodialysis
NCT00277693 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
NCT02502981 ·Status: UNKNOWN ·Phase: PHASE4
-
Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients
NCT03314493 ·Status: COMPLETED ·Phase: PHASE3
-
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825 ·Status: COMPLETED ·Phase: NA
-
Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study
NCT00403910 ·Status: COMPLETED ·Phase: PHASE3
-
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
NCT00498537 ·Status: COMPLETED ·Phase: NA
-
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?
NCT00291720 ·Status: COMPLETED ·Phase: PHASE2